Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br JS has performed the assays and drafted

    2020-08-18


    JS has performed the assays and drafted the manuscript.
    DH, LHM, and WHC have participated in the study design and manuscript drafting.
    HZ has participated in study design, data analysis, and manuscript drafting.
    Funding sources
    The Mexican American Cohort receives funds collected pursuant to the Comprehensive Tobacco Settlement of 1998 and appropriated by the 76th legislature to The University of Texas MD Anderson Cancer Center and from the Caroline W. Law Fund for Cancer Prevention and the Duncan Family Institute for Risk Assessment and Cancer Prevention.
    Declaration of interest
    All authors have declared no conflict of interest.
    Acknowledgements
    We thank the field staff for their ongoing work with participant recruitment and follow-up. Most importantly, we thank our study participants and their parents for their cooperation and participation, without which this Doxorubicin research would not be possible. We acknowledge the Department of Scientific Publications for editing the manuscript.
    References
    T. Dupre, G. Fagherazzi, F. Clavel-Chapelon, S. Mesrine, C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study, Cancer
    M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith Jr., K. Taubert, R.P. Tracy, F. Vinicor, Centers for Disease C, Prevention, American Heart A, Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association, Circulation 107 (3) (2003) 499–511. r>